Biocompatible dextran-coated gadolinium-doped cerium oxide nanoparticles as MRI contrast agents with high T1 relaxivity and selective cytotoxicity to cancer cells-Reference-Cited by-同舟云学术

Biocompatible dextran-coated gadolinium-doped cerium oxide nanoparticles as MRI contrast agents with high T1 relaxivity and selective cytotoxicity to cancer cells

Published:2021 Issue:33 Volume:9 Page:6586-6599
ISSN:2050-750X
Container-title:Journal of Materials Chemistry B
language:en
Short-container-title:J. Mater. Chem. B

Author:

Popov A. L.¹²^ORCID,Abakumov M. A.³⁴^ORCID,Savintseva I. V.²,Ermakov A. M.²,Popova N. R.²,Ivanova O. S.¹,Kolmanovich D. D.²,Baranchikov A. E.¹^ORCID,Ivanov V. K.¹^ORCID

Affiliation:

1. Kurnakov Institute of General and Inorganic Chemistry of the Russian Academy of Sciences, Leninsky av., 31, Moscow 119991, Russia

2. Institute of Theoretical and Experimental Biophysics of the Russian Academy of Sciences, Institutskaya, 3, Pushchino 142290, Russia

3. Department of Medical Nanobiotechnology, Pirogov Russian National Research Medical University, 117997 Moscow, Russia

4. Biomedical Nanomaterials Laboratory, National University of Science and Technology “MISiS”, Leninskiy prospect, 4, Moscow, 119049, Russia

Abstract

Dextran-coated gadolinium-modified ceria nanoparticles possess excellent colloidal stability, high r1-relaxivity, demonstrate efficient cell internalisation and selective cytotoxicity to cancer cells.

Funder

Ministry of Science and Higher Education of the Russian Federation

Publisher

Royal Society of Chemistry (RSC)

Subject

General Materials Science,Biomedical Engineering,General Chemistry,General Medicine

Link

http://pubs.rsc.org/en/content/articlepdf/2021/TB/D1TB01147B

Reference97 articles.

1. Synergistically Integrated Nanoparticles as Multimodal Probes for Nanobiotechnology

2. Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers

3. The effect of gadolinium-based contrast agent administration on magnetic resonance fingerprinting-based T1 relaxometry in patients with prostate cancer